Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Phathom Pharmaceuticals(US:PHAT) Globenewswire·2026-01-07 21:01FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.Preliminary Fourth Quarter 2025 Financial Results For the three months ended December 31, 2025, Phathom expects to report: Net revenues of approximately $57 million ...